Effect of statins on mortality and duration of mechanical ventilation in acute lung injury patients: A meta-analysis of five randomized controlled trials

International Journal of Clinical Pharmacology and Therapeutics

Volumn 53, Issue 11, 2015, Pages 923-932

  Yang, Ping ^a   Hong, Dong Sheng ^a   Chen, Jian ^c   Zheng, Xia ^a   Lu, Xiao Yang ^a   Du, Yong Zhong ^b   Zhang, Xing Guo ^a   Jiang, Sai Ping ^a  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b ZHEJIANG UNIVERSITY   (China)

^c NONE

Author keywords

Acute lung injury; Acute respiratory distress syndrome; Mechanical ventilation duration; Mortality; Statins

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ACUTE LUNG INJURY; ARTICLE; ARTIFICIAL VENTILATION; COMPUTER PROGRAM; DRUG EFFICACY; EXPERIMENTAL DESIGN; HUMAN; INFORMATION PROCESSING; INTENSIVE CARE UNIT; META ANALYSIS (TOPIC); MORTALITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT DURATION; TREATMENT OUTCOME; ADVERSE EFFECTS; CHI SQUARE DISTRIBUTION; META ANALYSIS; ODDS RATIO; RISK FACTOR; TIME;

ACUTE LUNG INJURY; CHI-SQUARE DISTRIBUTION; HOSPITAL MORTALITY; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; ODDS RATIO; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESPIRATION, ARTIFICIAL; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84946907027     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CP202340     Document Type: Article

References (66)

1. Bernard GR, Artigas A, Brigham KL, Carlet J, Falke K, Hudson L, Lamy M, Legall JR, Morris A, Spragg R. The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med. 1994; 149: 818-824. CrossRef PubMed
2. Ware LB, Matthay MA. The acute respiratory distress syndrome. N Engl J Med. 2000; 342: 1334-1349. CrossRef PubMed
3. Matthay MA, Zimmerman GA. Acute lung injury and the acute respiratory distress syndrome: four decades of inquiry into pathogenesis and rational management. Am J Respir Cell Mol Biol. 2005; 33: 319-327. CrossRef PubMed
4. Zhang S, Danchuk SD, Imhof KM, Semon JA, Scruggs BA, Bonvillain RW, Strong AL, Gimble JM, Betancourt AM, Sullivan DE, Bunnell BA. Comparison of the therapeutic effects of human and mouse adipose-derived stem cells in a murine model of lipopolysaccharide-induced acute lung injury. Stem Cell Res Ther. 2013; 4: 13. CrossRef PubMed
5. Chen XY, Wang SM, Li N, Hu Y, Zhang Y, Xu JF, Li X, Ren J, Su B, Yuan WZ, Teng XR, Zhang RX, Jiang DH, Mulet X, Li HP. Creation of lung-targeted dexamethasone immunoliposome and its therapeutic effect on bleomycin-induced lung injury in rats. PLoS ONE. 2013; 8: e58275. Cross-Ref PubMed
6. Reddy AT, Lakshmi SP, Reddy RC. The nitrated fatty acid 10-nitro-oleate diminishes severity of LPS-induced acute lung injury in mice. PPAR Res. 2012; 2012: 617063. CrossRef PubMed
7. Grommes J, Vijayan S, Drechsler M, Hartwig H, Mörgelin M, Dembinski R, Jacobs M, Koeppel TA, Binnebösel M, Weber C, Soehnlein O. Simvastatin reduces endotoxin-induced acute lung injury by decreasing neutrophil recruitment and radical formation. PLoS ONE. 2012; 7: e38917. CrossRef PubMed
8. Inoue H, Nakagawa Y, Ikemura M, Usugi E, Nata M. Molecular-biological analysis of acute lung injury (ALI) induced by heat exposure and/or intravenous administration of oleic acid. Leg Med (Tokyo). 2012; 14: 304-308. CrossRef PubMed
9. Levitt JE, Matthay MA. Clinical review: Early treatment of acute lung injury-paradigm shift toward prevention and treatment prior to respiratory failure. Crit Care. 2012; 16: 223. CrossRef PubMed
10. Bernard GR, Artigas A, Brigham KL, Carlet J, Falke K, Hudson L, Lamy M, LeGall JR, Morris A, Spragg R; Consensus Committee. Report of the American-European Consensus conference on acute respiratory distress syndrome: definitions, mechanisms, relevant outcomes, and clinical trial coordination. J Crit Care. 1994; 9: 72-81. Cross-Ref PubMed
11. Ranieri VM, Rubenfeld GD, Thompson BT, Ferguson ND, Caldwell E, Fan E, Camporota L, Slutsky AS; ARDS Definition Task Force. Acute respiratory distress syndrome: the Berlin Definition. JAMA. 2012; 307: 2526-2533. PubMed
12. Costa EL, Amato MB. The new definition for acute lung injury and acute respiratory distress syndrome: is there room for improvement? Curr Opin Crit Care. 2013; 19: 16-23. CrossRef PubMed
13. Liao JK, Laufs U. Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol. 2005; 45: 89-118. CrossRef PubMed
14. Wagner AH, Gebauer M, Güldenzoph B, Hecker M. 3-hydroxy-3-methylglutaryl coenzyme A reductase-independent inhibition of CD40 expression by atorvastatin in human endothelial cells. Arterioscler Thromb Vasc Biol. 2002; 22: 1784-1789. CrossRef PubMed
15. Chalmers JD, Short PM, Mandal P, Akram AR, Hill AT. Statins in community acquired pneumonia: Evidence from experimental and clinical studies. Respir Med. 2010; 104: 1081-1091. CrossRef PubMed
16. van de Visse EP, van der Heijden M, Verheij J, van Nieuw Amerongen GP, van Hinsbergh VW, Girbes AR, Groeneveld AB. Effect of prior statin therapy on capillary permeability in the lungs after cardiac or vascular surgery. Eur Respir J. 2006; 27: 1026-1032. PubMed
17. Katsiki N, Wierzbicki AS, Mikhailidis DP. Pulmonary arterial hypertension and statins: an update. Curr Opin Cardiol. 2011; 26: 322-326. CrossRef PubMed
18. Zeki AA, Bratt JM, Rabowsky M, Last JA, Kenyon NJ. Simvastatin inhibits goblet cell hyperplasia and lung arginase in a mouse model of allergic asthma: a novel treatment for airway remodeling? Transl Res. 2010; 156: 335-349. CrossRef PubMed
19. Ma Y, Wen X, Peng J, Lu Y, Guo Z, Lu J. Systematic review and meta-analysis on the association between outpatient statins use and infectious disease-related mortality. PLoS ONE. 2012; 7: e51548. CrossRef PubMed
20. Janda S, Young A, Fitzgerald JM, Etminan M, Swiston J. The effect of statins on mortality from severe infections and sepsis: a systematic review and meta-analysis. J Crit Care. 2010; 25: 656. e7-22. PubMed
21. Tleyjeh IM, Kashour T, Hakim FA, Zimmerman VA, Erwin PJ, Sutton AJ, Ibrahim T. Statins for the prevention and treatment of infections: a systematic review and meta-analysis. Arch Intern Med. 2009; 169: 1658-1667. CrossRef PubMed
22. Falagas ME, Makris GC, Matthaiou DK, Rafailidis PI. Statins for infection and sepsis: a systematic review of the clinical evidence. J Antimicrob Chemother. 2008; 61: 774-785. CrossRef PubMed
23. Rzouq F, Alahdab F, Olyaee M. Statins and hepatitis C virus infection: an old therapy with new scope. Am J Med Sci. 2014; 348: 426-430. Cross-Ref PubMed
24. Saliba W, Barnett-Griness O, Elias M, Rennert G. Statins use and risk of mortality in patient with Clostridium difficile infection. Clin Microbiol Infect. 2014; 20: 1061-1066. CrossRef PubMed
25. Shokouhi S, Alavi Darazam I, Sharifi G, Gachkar L, Amirsardari A, Samadian M. Statins and postoperative infections: a randomized clinical trial. Jundishapur J Microbiol. 2014; 7: e9456 PubMed.
26. Pasin L, Landoni G, Castro ML, Cabrini L, Belletti A, Feltracco P, Finco G, Carozzo A, Chiesa R, Zangrillo A. The effect of statins on mortality in septic patients: a meta-analysis of randomized controlled trials. PLoS ONE. 2013; 8: e82775. CrossRef PubMed
27. McAuley DF, Laffey JG, O'Kane CM, Perkins GD, Mullan B, Trinder TJ, Johnston P, Hopkins PA, Johnston AJ, McDowell C, McNally CHARP-2 Investigators; Irish Critical Care Trials Group. Simvastatin in the acute respiratory distress syndrome. N Engl J Med. 2014; 371: 1695-1703. CrossRef PubMed
28. Truwit JD, Bernard GR, Steingrub J, Matthay MA, Liu KD, Albertson TE, Brower RG, Shanholtz C, Rock P, Douglas IS, deBoisblanc BP, Hough CL, Hite RD, Thompson BT; National Heart, Lung, and Blood Institute ARDS Clinical Trials Network. Rosuvastatin for sepsis-associated acute respiratory distress syndrome. N Engl J Med. 2014; 370: 2191-2200. CrossRef PubMed
29. Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration. 2011; Available from www.cochranehandbook.org on March 21st 2011.
30. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002; 21: 1539-1558. CrossRef PubMed
31. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003; 327: 557-560. CrossRef PubMed
32. Peters JL, Sutton AJ, Jones DR, Abrams KR, Rushton L. Contour-enhanced meta-analysis funnel plots help distinguish publication bias from other causes of asymmetry. J Clin Epidemiol. 2008; 61: 991-996. CrossRef PubMed
33. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997; 315: 629-634. Cross-Ref PubMed
34. McAuley DF, O'Kane CM, Craig TR, Shyamsundar M, Herwald H, Dib K. Simvastatin decreases the level of heparin-binding protein in patients with acute lung injury. BMC Pulm Med. 2013; 13: 47 CrossRef PubMed
35. Kor DJ, Iscimen R, Yilmaz M, Brown MJ, Brown DR, Gajic O. Statin administration did not influence the progression of lung injury or associated organ failures in a cohort of patients with acute lung injury. Intensive Care Med. 2009; 35: 1039-1046. CrossRef PubMed
36. Group TICCT; Irish Critical Care Trials Group. Acute lung injury and the acute respiratory distress syndrome in Ireland: a prospective audit of epidemiology and management. Crit Care. 2008; 12: R30. CrossRef PubMed
37. Craig TR, Duffy MJ, Shyamsundar M, McDowell C, O'Kane CM, Elborn JS, McAuley DF. A randomized clinical trial of hydroxymethylglutarylcoenzyme a reductase inhibition for acute lung injury (The HARP Study). Am J Respir Crit Care Med. 2011; 183: 620-626. CrossRef PubMed
38. Papazian L, Roch A, Charles PE, Penot-Ragon C, Perrin G, Roulier P, Goutorbe P, Lefrant JY, Wiramus S, Jung B, Perbet S, Hernu R, Nau A, Baldesi O, Allardet-Servent J, Baumstarck K, Jouve E, Moussa M, Hraiech S, Guervilly C, et al; STATIN-VAP Study Group. Effect of statin therapy on mortality in patients with ventilator-associated pneumonia: a randomized clinical trial. JAMA. 2013; 310: 1692-1700. CrossRef PubMed
39. Makris D, Manoulakas E, Komnos A, Papakrivou E, Tzovaras N, Hovas A, Zintzaras E, Zakynthinos E. Effect of pravastatin on the frequency of ventilator-associated pneumonia and on intensive care unit mortality: open-label, randomized study. Crit Care Med. 2011; 39: 2440-2446. CrossRef PubMed
40. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLos Med. 2009; 6: e10097. CrossRef PubMed
41. Hardaway RM. A brief overview of acute respiratory distress syndrome. World J Surg. 2006; 30: 1829-1834., discussion 1835. CrossRef PubMed
42. Ware LB. Pathophysiology of acute lung injury and the acute respiratory distress syndrome. Semin Respir Crit Care Med. 2006; 27: 337-349. CrossRef PubMed
43. Bastarache JA, Ware LB, Bernard GR. The role of the coagulation cascade in the continuum of sepsis and acute lung injury and acute respiratory distress syndrome. Semin Respir Crit Care Med. 2006; 27: 365-376. CrossRef PubMed
44. Johnson ER, Matthay MA. Acute lung injury: epidemiology, pathogenesis, and treatment. J Aerosol Med Pulm Drug Deliv. 2010; 23: 243-252. CrossRef PubMed
45. Epstein M, Campese VM. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors on renal function. Am J Kidney Dis. 2005; 45: 2-14. CrossRef PubMed
46. Yasuda H, Yuen PS, Hu X, Zhou H, Star RA. Simvastatin improves sepsis-induced mortality and acute kidney injury via renal vascular effects. Kidney Int. 2006; 69: 1535-1542. CrossRef PubMed
47. Gueler F, Rong S, Park JK, Fiebeler A, Menne J, Elger M, Mueller DN, Hampich F, Dechend R, Kunter U, Luft FC, Haller H. Postischemic acute renal failure is reduced by short-term statin treat ment in a rat model. J Am Soc Nephrol. 2002; 13: 2288-2298. CrossRef PubMed
48. Laufs U, La Fata V, Plutzky J, Liao JK. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation. 1998; 97: 1129-1135. CrossRef PubMed
49. Chen L, Nakano K, Kimura S, Matoba T, Iwata E, Miyagawa M, Tsujimoto H, Nagaoka K, Kishimoto J, Sunagawa K, Egashira K. Nanoparticlemediated delivery of pitavastatin into lungs ameliorates the development and induces regression of monocrotaline-induced pulmonary artery hypertension. Hypertension. 2011; 57: 343-350. CrossRef PubMed
50. Laufs U, Marra D, Node K, Liao JK. 3-Hydroxy-3-methylglutaryl-CoA reductase inhibitors attenuate vascular smooth muscle proliferation by preventing rho GTPase-induced down-regulation of p27(Kip1). J Biol Chem. 1999; 274: 21926-21931. CrossRef PubMed
51. Yang Z, Kozai T, van der Loo B, Viswambharan H, Lachat M, Turina MI, Malinski T, Lüscher TF. HMG-CoA reductase inhibition improves endothelial cell function and inhibits smooth muscle cell proliferation in human saphenous veins. J Am Coll Cardiol. 2000; 36: 1691-1697. CrossRef PubMed
52. Lacoste L, Lam JY, Hung J, Letchacovski G, Solymoss CB, Waters D. Hyperlipidemia and coronary disease. Correction of the increased thrombogenic potential with cholesterol reduction. Circulation. 1995; 92: 3172-3177. CrossRef PubMed
53. Alfon J, Royo T, Garcia-Moll X, Badimon L. Platelet deposition on eroded vessel walls at a stenotic shear rate is inhibited by lipid-lowering treatment with atorvastatin. Arterioscler Thromb Vasc Biol. 1999; 19: 1812-1817. CrossRef PubMed
54. Naidu BV, Woolley SM, Farivar AS, Thomas R, Fraga C, Mulligan MS. Simvastatin ameliorates injury in an experimental model of lung ischemiareperfusion. J Thorac Cardiovasc Surg. 2003; 126: 482-489. CrossRef PubMed
55. Pirat A, Zeyneloglu P, Aldemir D, Yücel M, Ozen O, Candan S, Arslan G. Pretreatment with simvastatin reduces lung injury related to intestinal ischemia-reperfusion in rats. Anesth Analg. 2006; 102: 225-232. CrossRef PubMed
56. Jain R, DalNogare A. Pharmacological therapy for acute respiratory distress syndrome. Mayo Clin Proc. 2006; 81: 205-212. CrossRef PubMed
57. Yokota N, O'Donnell M, Daniels F, Burne-Taney M, Keane W, Kasiske B, Rabb H. Protective effect of HMG-CoA reductase inhibitor on experimental renal ischemia-reperfusion injury. Am J Nephrol. 2003; 23: 13-17. CrossRef PubMed
58. Pruefer D, Makowski J, Schnell M, Buerke U, Dahm M, Oelert H, Sibelius U, Grandel U, Grimminger F, Seeger W, Meyer J, Darius H, Buerke M. Simvastatin inhibits inflammatory properties of Staphylococcus aureus alpha-toxin. Circulation. 2002; 106: 2104-2110. CrossRef PubMed
59. Shyamsundar M, McKeown ST, O'Kane CM, Craig TR, Brown V, Thickett DR, Matthay MA, Taggart CC, Backman JT, Elborn JS, McAuley DF. Simvastatin decreases lipopolysaccharide-induced pulmonary inflammation in healthy volunteers. Am J Respir Crit Care Med. 2009; 179: 1107-1114. CrossRef PubMed
60. Kruger P, Bailey M, Bellomo R, Cooper DJ, Harward M, Higgins A, Howe B, Jones D, Joyce C, Kostner K, McNeil J, Nichol A, Roberts MS, Syres G, Venkatesh B; ANZ-STATInS Investigators-ANZICS Clinical Trials Group. A multicenter randomized trial of atorvastatin therapy in intensive care patients with severe sepsis. Am J Respir Crit Care Med. 2013; 187: 743-750. CrossRef PubMed
61. Hu M, Tomlinson B. Evaluation of the pharmacokinetics and drug interactions of the two recently developed statins, rosuvastatin and pitavastatin. Expert Opin Drug Metab Toxicol. 2014; 10: 51-65. CrossRef PubMed
62. Gao F, Linhartova L, Johnston AM, Thickett DR. Statins and sepsis. Br J Anaesth. 2008; 100: 288-298. CrossRef PubMed
63. Bellosta S, Paoletti R, Corsini A. Safety of statins: focus on clinical pharmacokinetics and drug interactions. Circulation. 2004; 109 (Suppl 1): III50-III57. CrossRef PubMed
64. Abd TT, Jacobson TA. Statin-induced myopathy: a review and update. Expert Opin Drug Saf. 2011; 10: 373-387. CrossRef PubMed
65. Maji D, Shaikh S, Solanki D, Gaurav K. Safety of statins. Indian J Endocrinol Metab. 2013; 17: 636-646. CrossRef PubMed
66. Rubenfeld GD, Caldwell E, Peabody E, Weaver J, Martin DP, Neff M, Stern EJ, Hudson LD. Incidence and outcomes of acute lung injury. N Engl J Med. 2005; 353: 1685-1693. CrossRef PubMed